Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
pharmaphorum2h
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
precisionmedicineonline1h
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
New Study Uncovers a Shocking Side Effect of a Parkinson’s Drug
A new study reveals that entacapone, a drug used to treat Parkinson’s disease, significantly disrupts the gut microbiome by ...
BioSpace2dOpinion
Opinion: Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1
With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...
chromatographyonline16d
Understanding the On-off Retention Mechanism of Oligonucleotides
A team from the University of Geneva and Bayer AG present their findings on the on-off retention of oligonucleotides and the ...
Hosted on MSN4d
Scientists develop microcellular drones to deliver cancer-killing drugs
Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...
BioSpace1d
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...